An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Philip Morris International Inc. Declares Regular Quarterly Dividend of $1.25 Per Share
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
dividends
Rhea-AI Summary
The Board of Directors of Philip Morris International (NYSE: PM) has declared a quarterly dividend of $1.25 per common share, set to be paid on April 12, 2022, to shareholders of record as of March 24, 2022. The ex-dividend date is March 23, 2022. PMI continues its transition towards a smoke-free future, having invested over USD 9 billion since 2008 in developing smoke-free products like IQOS, which is now available in 71 markets and has attracted around 15.3 million adult users who have quit smoking.
Positive
Quarterly dividend of $1.25 reflects confidence in company performance.
Over $9 billion invested in smoke-free product development since 2008.
IQOS has successfully attracted 15.3 million adult users who have ceased smoking.
Negative
None.
NEW YORK--(BUSINESS WIRE)--
Regulatory News:
The Board of Directors of Philip Morris International Inc. (NYSE: PM) today declared a regular quarterly dividend of $1.25 per common share, payable on April 12, 2022, to shareholders of record as of March 24, 2022. The ex-dividend date is March 23, 2022. For more details on stock, dividends and other information, see www.pmi.com/dividend.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration (FDA) has authorized the marketing of a version of PMI’s IQOS Platform 1 device and consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. As of December 31, 2021, PMI's smoke-free products are available for sale in 71 markets, and PMI estimates that approximately 15.3 million adults around the world have already switched to IQOS and stopped smoking. With a strong foundation and significant expertise in life sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet patient and consumer needs. For more information, please visit www.pmi.com and www.pmiscience.com.
